Inherited and acquired thrombophilia: Pregnancy outcome and treatment

Reproductive Toxicology

Volumn 22, Issue 2, 2006, Pages 227-233

  De Santis, Marco ^a   Cavaliere, A F ^a   Straface, G ^a   Di Gianantonio, E ^b   Caruso, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acquired thrombophilia; Anticoagulant therapy; Inherited thrombophilia; IUGR; Placenta abruption; Pre eclampsia; Pregnancy outcome; Spontaneous abortion

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; CARDIOLIPIN ANTIBODY; COUMARIN DERIVATIVE; DALTEPARIN; DANAPAROID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANT THERAPY; AUTOIMMUNE THROMBOCYTOPENIA; DRUG SAFETY; EMBRYOPATHY; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNE MEDIATED INJURY; INTRAUTERINE GROWTH RETARDATION; NEONATAL HEMORRHAGE; OSTEOPOROSIS; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DISORDER; PREGNANCY OUTCOME; RECURRENT DISEASE; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ABORTION, SPONTANEOUS; ABRUPTIO PLACENTAE; ANTICOAGULANTS; ASPIRIN; FEMALE; FETAL GROWTH RETARDATION; HEPARIN; HUMANS; PRE-ECLAMPSIA; PREGNANCY; THROMBOPHILIA;

EID: 33745634384     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2006.05.002     Document Type: Review

References (65)

1. Walker I.D., Greaves M., and Preston F.E. On behalf of the haemostasis and thrombosis task force British Committee for standards in haematology. Investigation and management of heritable thrombophilia. Br J Haematology 114 (2001) 512-528
2. Martinelli I., De Stefano V., and Taioli E. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87 (2002) 791-795
3. Triplett D.A., and Harris E.N. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol 21 (1989) 123-131
4. Sanson B.J., Friederich P.W., and Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75 (1996) 387-388
5. Meinardi J.R., Middeldorp S., de Kam M.M., van Pampus E.C., Hamulyac K., Prins M.H., et al. Increased risk for fetal loss in carrierrs of the factor V Leiden mutation. Ann Intern Med 130 (1999) 736-739
6. Wramsby M.L., Sten-Linder M., and Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 74 5 (2000) 987-991
7. Hashimoto K., and Shizusawa Y. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod Embr 14 (1999) 1872-1874
8. Murphy R.P., Donoghue C., Nallen R.J., and D'Mello M. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylennetetrahydrofolate reductase polymorphism in pregnancy. Arterioscler Thromb Vasc Biol 20 (2000) 266-270
9. Lindqvist P.G., Svensson P.J., Marsaal K., Luterkort M., and Dahlback B. Activated protein C resistance (FV: Q506) and pregnancy. Thromb Haemost 81 (1999) 532-537
10. Rai R., Shlebak A., Cohen A., and Backos M. Factor V Leiden and acquired activated protein C resistance among women with recurrent miscarriage. Hum Reprod 16 (2001) 961-965
11. Santoro R., Iannaccaro P., and Sottilotta G. Prothrombotic gene mutations in women with recurrent abortions and intrauterine fetal death. Minerva Ginecol 57 (2005) 447-450
12. Gluck C.J., Pranikoff J., Aregawi D., Haque M., Zhu B., Yracy T., et al. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriages. Metabolism 54 (2005) 1345-1349
13. Lissalde-Lavigne G., and Cochery-Nouvellon E. The association between hereditary thrombophilias and pregnancy loss. Haematologica 90 (2005) 1223-1230
14. Sugiura M. Pregnancy and delivery in protein C-deficiency. Curr Drug Targets 6 (2005) 577-583
15. Hossain N., Shamsi T., and Soomro N. Frequency of thrombophilia in patients with adverse pregnancy outcome. J Pak Med Assoc 55 (2005) 245-247
16. Behjati R., Modarressi M.H., Jeddi-Therani M., Dokoohaki P., Gashemi J., Zarnani A.H., et al. Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. Ann Hematol 1 (2006) 1-4
17. Jivray S., Rai R., Underwood J., and Regan L. Genetic thrombophilic mutations among couples with recurrent miscarriage. Hum Reprod (2006) 23
18. Weintraub AY, Sheiner E, Levy A, Yerushalmi R, Mazor M. Pregnancy complications in women with inherited thrombophilia. Arch Gynecol Obstet; 2006.
19. Robertson L., Wu O., and Langhorne P. Thrombophilia in pregnancy: a aystematic review. Br J Haematol 132 (2006) 171-196
20. Dekker G.A., de Vries J.I., and Doelitzsch P.M. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gnnecol 173 (1995) 1042-1048
21. Dekker G.A. Risk factor for preeclampsia. Clin Obstet Gynecol 42 (1999) 422-435
22. Dizon-Townson D.S., Nelson L.M., Easton K., and Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 175 (1996) 902-905
23. Grandone E., Margaglione M., and Colaizzo D. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 77 (1997) 1052-1054
24. Nagy B., Toth B., Rigo J., Karadi I., Romics L., and Papp Z. Detection of factor V Leiden mutation in severe preeclamtic Hungarian women. Clin Genet 53 (1998) 478-481
25. Kupferminc M.J., Fait G., Many A., Gordon D., Eldor A., and Lessing J.B. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 96 (2000) 45-49
26. Lindoff C., Ingemarsson I., Martinsson G., and Segelmark M. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 176 (1997) 457-460
27. Sohda A., Arinami T., and Hamada H. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 34 (1997) 525-526
28. Rajkovic A., Catalano P.M., and Malinow M.R. Elevated homocysteine levels with preeclampsia. Thromb Haemost 77 (1997) 1052-1054
29. El-Khairy L., Vollset S.E., Refsum H., and Ueland P.M. Plasma total cysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordland Homocysteine Study. Am J Clin Nutr 77 (2003) 467-472
30. Van Pampus M.G., Dekker G.A., Wolf H., and Huijgens P.C. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 182 (2000) 989-990
31. Van Pampus M.G., Wolf H., Koopman M.M., van der Ende A., Buller H.R., and Reitsma P.H. Prothrombin 20210 G: a mutation and factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome. Hypertens Pregnancy 20 (2001) 291-298
32. Kosmas I.P., Tatsioni A., and Ioannidis J.P. Association of Leiden mutation in factor V gene with hypertension in pregnancy and preeclampsia: a meta-analysis. J Hypertens 21 (2003) 1221-1228
33. Kosmas I.P., Tatsioni A., and Ioannidis J.P. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and preeclampsia: a meta-analysis. J Hypertens 22 (2004) 1655-1662
34. D'Anna R., Baviera G., Corrado F., Ientile R., Granese D., and Stella N.C. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet Gynecol Scand 83 (2004) 155-158
35. Mello G., Parretti E., Marozio L., Pizzi C., Lojacono A., Frusca T., et al. Trombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 46 (2005) 1252-1253
36. Sibai B.M. Thrombophilia and severe preeclampsia: time to screen and treat in future pregnancies?. Hypertension 46 (2005) 1252-1255
37. Clark P., Walker I.D., and Greer I. Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight. Lancet 353 (1999) 292-293
38. Kupferminc M.J., Eldor A., and Steinman N. Increased frequency of genetic trombophilia in women with complications of pregnancy. N Engl J Med 340 (1999) 9-130
39. Kupferminc M.J., Peri H., and Zwang E. High prevalence of the prothromin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 79 (2000) 963-967
40. Martinelli P., Grandone E., Colaizzo D., Paladini D., Sciannama N., Margaglione M., et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 86 (2001) 428-431
41. Infante-Rivard C., Rivard G.E., and Yotov W.V. Absence of association of thrombophilia polymorphism with intrauterine growth restriction. N Engl J Med 347 (2002) 19-25
42. Infante-Rivard C., Rivard G.E., Gauthiter R., and Theoret Y. Unexpected relationship between plasma homocysteine and intrauterine growth restriction. Clin Chem 49 (2003) 1476-1482
43. Infante-Rivard C., Rivard G.E., Guiguet M., and Gauthier R. Thrombophlic polymorphisms and intrauterine growth restriction. Thrombophilic polymorphism and intrauterine growth restriction. Epidemiology 16 (2005) 281-287
44. Howley H.E., Walker M., and Rodger M.A. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 192 (2005) 694-708
45. Wiener-Megnagi Z., Ben-Shlomo I., Goldberg Y., and Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 179 (1998) 1565-1567
46. Van der Molen E.F., and Verbruggen B. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG 107 (2000) 785-791
47. Facchinetti F., Marozio L., Grandone E., Pizzi C., Volpe A., and Benedetto C. Thrombophilic mutations are a main risk factor for placental abruption. Haematologica 88 (2003) 785-788
48. Prochazka M., Happach C., and Marsal K. Factor V Leiden in pregnancies complicated by placental abruption. BJOG 110 (2003) 462-466
49. Bates S.M., Greer I.A., Hirsh J., and Giinsberg J.S. Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 627S-644S
50. Grandone E., Guiotto G., and Di Minno G. Linee guida sull'uso dei farmaci anticoagulanti e antiaggreganti in ostetricia e ginecologia. Haematologica 87 S12 (2002) 1-20
51. Greer I.A., and Nelson-Pierci C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005) 401-407
52. Monreal M., Lafoz E., Olive A., Del Rio L., and Vedia C. Comparison of subcutaneos unfractionated heparin with a low-molecular weight heparin (Fragmin) in patients with venous thromoembolism and contraindications for coumarin. Thromb Haemost 71 (1994) 7-11
53. Pettila V., Leinonen P., Markkola A., Hiilesmaa V., and Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87 (2002) 182-186
54. Sanson B.J., Lensing A.W., Prins M.H., Ginsberg J.S., Barkagan Z.S., Lavenne-Pardonge E., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 5 (1999) 668-672
55. Boda Z., Laszlo P., Rejto L., Tornai I., Pflieger G., Blasko G., et al. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Thromb Haemost 76 1 (1996) 128
56. Hunt B.J., Doughty H.A., Majumdar, Copplestone A., Kerslake S., Buchanan N., et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Throm Haemost 77 1 (1997) 39-43
57. Lindqvist P.G., and Dahlback B. Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy. Thromb Haemost 84 1 (2000) 140-141
58. Reports of epidural or spinal haematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. Food and Drug Administration, Washington; December 1997.
59. Sugiyama T., Itoh M., Ohtawa M., and Natsuga T. Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics. Thromb Res 68 2 (1992) 119-129
60. Chan W.S., Anand S., and Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160 2 (2000) 191-196
61. Calderwood C.J., and Geer I.A. The role of factor V Leiden in maternal health and the outcome of pregnancy. Curr Drug Targets 6 (2005) 567-576
62. Martinelli I., Taioli E., Cetin I., Marinoni A., Gerosa S., Villa M.V., et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 343 14 (2000) 1015-1018
63. Rey E., Kahn S.R., David M., and Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 9361 (2003) 901-908
64. Nelen W.L., Blom H.J., Steegers E.A., den Heijer M., and Eskes T.K. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 74 6 (2000) 1196-1199
65. Gris J.C., Perneger T.V., Quere I., Mercier E., Fabbro-Peray P., Lavigne-Lissalde G., et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 102 10 (2003) 3504-3513